Charles River and BioTech Social Inc. Join Forces to Enhance Crowdfunding for Cell and Gene Therapy Developers

Charles River Laboratories and BioTech Social Inc. are exploring a strategic partnership to enable crowdfunding for cell and gene therapy developers. The partnership aims to accelerate therapy development and commercialization by providing access to the BioTech Funding Portal, which allows companies to raise up to $5 million annually. The collaboration seeks to overcome the funding "valley of death" in the biotech industry and support Charles River's Incubator and Accelerator Programs.

Charles River Laboratories International, Inc. (NYSE: CRL) and BioTech Social Inc. (BSI) have announced an exploration into a strategic partnership to enhance their Incubator (CIP) and Accelerator (CAP) Programs by integrating crowdfunding features. The collaboration aims to provide early-stage cell and gene therapy (CGT) developers with access to the BioTech Funding Portal, an investment crowdfunding platform for life science companies.

The potential partnership would allow participants in the CIP and CAP programs to raise up to $5 million annually via the BioTech Funding Portal. This platform, a subsidiary of BSI, exclusively lists life sciences companies and acts as a conduit for crowdfunding of emerging biotech companies. The mission of the BioTech Funding Portal is to harness the power of non-accredited investors to support research that might otherwise go unfunded, despite addressing clear, unmet medical needs.

Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing at Charles River, expressed enthusiasm about the collaboration, stating, "We’re thrilled to explore this collaboration that will open up an exciting new funding pathway to bridge innovation with the right audiences and investors. This dynamic approach would potentially streamline the delivery of medicine to patients."

Neva West, PhD, CEO of BioTech Funding Portal, added, "Through our potential partnership with the CIP and CAP programs, we aim to help selected applicants cross the notorious funding ‘valley of death’ that so often threatens innovative, early-stage companies."

The CIP and CAP programs, established in 2024, have already shown success. The inaugural CIP cohort was announced in April 2025, and developers are now invited to apply for the next cohort. Subject to further agreement, applications may be jointly evaluated by Charles River and BioTech Social and possibly shortlisted in conjunction with the upcoming European Cell and Gene Therapy Summit in September.

Chih-Wen Ni, Founder and CEO of NVI Therapeutics and a participant in CIP, highlighted the value of Charles River's support, noting, "As a new pharmaceutical company, there are many aspects where you need consulting support. For instance, navigating regulations and conducting pre-clinical studies require expert assistance. Charles River is a leading contract development and manufacturing organization (CDMO) and their support is invaluable. I look forward to utilizing it to guide my company through the entire process."

Charles River has significantly broadened its cell and gene therapy portfolio with several acquisitions and expansions to meet growing demand for plasmid DNA, viral vector, and cell therapy services. The company's legacy discovery, safety, and testing capabilities, combined with its CDMO solutions, offer an industry-leading "concept to cure" advanced therapies solution.

The partnership between Charles River and BioTech Social Inc. seeks to accelerate therapy development and commercialization, providing early-stage developers with critical funding and support. The collaboration is a step forward in addressing the funding challenges faced by innovative biotech companies.

References:
[1] https://finance.yahoo.com/news/charles-river-biotech-social-inc-120000148.html
[2] https://www.stocktitan.net/news/CRL/charles-river-and-bio-tech-social-inc-pursue-crowdfunding-hxoonpu32sph.html